McMillan Office’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
McMillan Office's VRTX Position: Q2 2026 in Review
McMillan Office held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 300 shares worth $149K. The position accounts for 0.02% of the portfolio, ranked #211.
McMillan Office first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- McMillan Office held 300 shares of Vertex Pharmaceuticals worth $149K as of Q2 2026.
- McMillan Office left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
- Vertex Pharmaceuticals made up 0.02% of McMillan Office's portfolio in Q2 2026, its #211 holding.
- McMillan Office first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.